Table 1.
Baseline characteristics of 937 study participants with known coronary heart disease stratified by the presence of inducible ischemia.*
| Variable | Ischemia N=228 | No ischemia N=709 | P value |
|---|---|---|---|
| Age | 70±10 | 66±11 | < .0001 |
| Male sex | 200(88%) | 580(82%) | .04 |
| White race | 157(69%) | 412(58%) | .004 |
| History of: | |||
| Hypertension | 162(71%) | 493(70%) | .7 |
| Myocardial infarction | 150(66%) | 346(49%) | < .0001 |
| Congestive heart failure | 56(25%) | 100(14%) | .0003 |
| Stroke | 39(17%) | 88(12%) | .1 |
| Diabetes | 64(28%) | 169(24%) | .2 |
| Coronary revascularization | 147(64%) | 415(59%) | .1 |
| CABG | 112(49%) | 232(33%) | <.0001 |
| PCI | 82(36%) | 290(41%) | .17 |
| Current smoking | 40(18%) | 143(20%) | .4 |
| Regular alcohol use | 60(26%) | 214(30%) | .3 |
| Physically active | 147(64%) | 465(66%) | .7 |
| Body mass index | 28±5 | 28±5 | .2 |
| Medications | |||
| Beta blocker | 139(61%) | 406(57%) | .3 |
| Statin | 153(67%) | 458(65%) | .5 |
| Renin-angiotensin inhibitor | 139(61%) | 343(48%) | .0009 |
| Aspirin | 182(80%) | 554(78%) | .6 |
| Labs | |||
| Total cholesterol | 177±41 | 177±42 | .9 |
| HDL | 46±16 | 46±13 | .9 |
| LDL | 104±33 | 103±33 | .9 |
| Glycosylated hemoglobin | 6.2±1.3 | 5.9±1.1 | .0007 |
| Creatinine clearance | 74±26 | 85±28 | < .0001 |
| Log C-reactive protein | 0.77±1.3 | 0.65±1.3 | .2 |
| Log NT-proBNP | 5.85±1.2 | 4.96±1.2 | <.0001 |
| LV ejection fraction | 0.59±0.11 | 0.63±0.09 | <.0001 |
| Systolic blood pressure | 130±18 | 132±19 | 0.09 |
| Diastolic blood pressure | 70±10 | 75±10 | <.0001 |
| Weekly or more angina | 40(18%) | 131(18%) | 0.75 |
| Treadmill exercise capacity (METS) | 6.3±2.9 | 7.6±3.4 | <.0001 |
| Exercise stopped due to chest pain | 13(6%) | 21(3%) | .05 |
*
values are reported as % or mean ± standard deviation